Skip to main content

Recombinant Human Noggin GMP Protein, CF GMP

R&D Systems, part of Bio-Techne | Catalog # 6057-GMP

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
6057-GMP-100
6057-GMP-025
6057-GMP-01M

Key Product Details

Source

NS0

Accession #

Structure / Form

Disulfide-linked homodimer

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Mouse myeloma cell line, NS0-derived human Noggin protein
Gln28-Cys232
Manufactured and tested under current Good Manufacturing Practice (GMP) guidelines.

Purity

>95%, by SDS-PAGE with silver staining, under reducing conditions.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Amino acid sequencing was blocked, suggesting it is consistent with Gln28 as the first N-terminal amino acid.
Predicted N-terminal sequence: Gln-His-Tyr-Leu-His-Ile-Arg-Pro-Ala-Pro

Predicted Molecular Mass

23 kDa (monomer)

SDS-PAGE

30-33 kDa, reducing conditions

Activity

Measured by its ability to inhibit BMP-4-induced alkaline phosphatase production by ATDC5 mouse chondrogenic cells.
The ED50 for this effect is 0.02-0.16 μg/mL in the presence of 50 ng/mL of Recombinant Human BMP‑4 (Catalog # 314-BP).

Host Cell Protein

< 1.0 ng per μg of protein when tested by ELISA.

Mycoplasma

Negative for Mycoplasma.

Reviewed Applications

Read 1 review rated 4 using 6057-GMP in the following applications:

Scientific Data Images for Recombinant Human Noggin GMP Protein, CF

Recombinant Human Noggin GMP Protein Bioactivity

Recombinant Human Noggin GMP Protein Bioactivity

GMP-grade Recombinant Human Noggin (Catalog # 6057-GMP) inhibits BMP-4-induced alkaline phosphatase production in the ATDC5 mouse chondrogenic cell line. The ED50 for this effect is 0.04-0.2 µg/mL in the presence of 50 ng/mL of Recombinant Human BMP-4 (Catalog # 314-BP).
Recombinant Human Noggin GMP Protein SDS-PAGE

Recombinant Human Noggin GMP Protein SDS-PAGE

1 μg/lane of GMP-grade Recombinant Human Noggin (Catalog # 6057-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by silver staining, showing bands at 31 kDa and 57 kDa, respectively.

Formulation, Preparation and Storage

6057-GMP
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution Reconstitute at 100 μg/mL in PBS.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.

Background: Noggin

Noggin is a secreted homodimeric glycoprotein that is an antagonist of bone morphogenetic proteins (BMPs) (1, 2). Human Noggin cDNA encodes a 232 amino acid (aa) precursor protein; cleavage of a 19 aa signal peptide generates the 213 aa mature protein which contains an N-terminal acidic region, a central basic heparin‑binding segment and a C-terminal cysteine-knot structure (2). Secreted Noggin probably remains close to the cell surface due to its binding of heparin‑containing proteoglycans (3). Noggin is very highly conserved among vertebrates, such that mature human Noggin shares 99%, 99%, 98%, 97% and 89% aa sequence identity with mouse, rat, bovine, equine and chicken Noggin, respectively. Noggin binds some BMPs such as BMP-4 with high affinity and others such as BMP-7 with lower affinity. It antagonizes BMP bioactivities by blocking epitopes on BMPs that are needed for binding to both type I and type II receptors (2, 4). During embryogenesis, Noggin antagonizes specific BMPs at defined times, for example, during neural tube, somite and cardiomyocyte growth and patterning (5-7). During skeletal development, Noggin prevents chondrocyte hyperplasia, thus allowing proper formation of joints (4). Mutations within the cysteine-knot region of human Noggin are linked to multiple types of skeletal dysplasias that result in apical joint fusions (8). Noggin is expressed in defined areas of the adult central nervous system and peripheral tissues such as lung, skeletal muscle and skin (1). During culture of human embryonic stem cells (hESC) or neural stem cells under certain conditions, addition of Noggin to antagonize BMP activity may allow stem cells to proliferate while maintaining their undifferentiated state, or alternatively, to differentiate into dopaminergic neurons (6, 9 - 13). Noggin also appears to maintain adult stem cell populations in-vivo, for example, maintaining neural stem cells within the hippocampus (13).

References

  1. Valenzuela, D.M. et al. (1995) J. Neurosci. 15:6077.
  2. Groppe, J. et al. (2002) Nature 420:636.
  3. Paine-Saunders, S et al. (2002) J. Biol. Chem. 277:2089.
  4. Brunet, L. J. et al. (1998) Science 280:1455.
  5. McMahon, J. A. et al. (1998) Genes Dev. 12:1438.
  6. Itsykson, P. et al. (2005) Mol. Cell. Neurosci. 30:24.
  7. Yuasa, S. et al. (2005) Nat. Biotechnol. 23:607.
  8. Gong, Y. et al. (1999) Nat. Genet. 21:302.
  9. Xu, R.-H. et al. (2005) Nat. Methods 2:185.
  10. Wang, G. et al. (2005) Biochem. Biophys. Res. Commun. 330:934.
  11. Chaturvedi, G. et al. (2009) Cell Prolif. 42:425.
  12. Chiba, S. et al. (2008) Stem Cells 26:2810.
  13. Bonaguidi, M.A. et al. (2008) J. Neurosci. 28:9194.

Alternate Names

NOG, SYM1, SYNS1, SYNS1A

Entrez Gene IDs

9241 (Human); 18121 (Mouse)

Gene Symbol

NOG

UniProt

Additional Noggin Products

Product Documents for Recombinant Human Noggin GMP Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Manufacturing Specifications

GMP Proteins
R&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Eu. Ph. 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.


R&D Systems' quality focus includes:

  • Manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
  • Documented processes and QA control of documentation and process changes
  • Personnel training programs
  • Raw material testing and vendor qualification/monitoring
  • Fully validated equipment, processes and test methods
  • Equipment calibration schedules using a computerized calibration program
  • Facility maintenance, safety programs and pest control
  • Material review process for variances
  • Monitoring of stability over product shelf-life


R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information:

  • N-terminal amino acid analysis, SDS-PAGE analysis, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot
  • Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial testing according to USP
  • Host Cell Protein testing performed by ELISA


Additional testing and documentation requested by the customer can be arranged at an additional cost.

Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems in Minneapolis, Minnesota USA.

R&D Systems sells GMP grade products for preclinical or clinical ex vivo use. They are not for in vivo use. Please read the following End User Terms prior to using this product.

Product Specific Notices for Recombinant Human Noggin GMP Protein, CF

Full terms and conditions of sale can be found online in the Protein Sciences Segment T&Cs at: Terms & Conditions.

For preclinical, or clinical ex vivo use

Loading...
Loading...
Loading...